What Should Your Potential Investors Want to Know? Building a Compelling Case to Attract Capital for Your Diagnostics Laboratory


In our complimentary webcast, two of the industry's leading experts on laboratory commercialization, Rina Wolf and Lew Schuster, provide guidance on how early stage or emerging laboratories can distinguish themselves in a competitive funding environment. Do you know what you need to have in place to attract funding partners?


We'll cover:


  • Understanding investors' issues with validation and adoption
  • Differentiating your laboratory in a crowded funding environment
  • Anticipating and preparing for investor questions
  • Recognizing what investors should be asking, and developing a strategy to steer due diligence in the right direction
  • Responding to questions about your reimbursement strategies

In an environment where investment and innovation are being suppressed by a lack of clear regulatory or coverage paths, it is imperative for young labs to understand the current atmosphere. What are investors looking for, and what should they really be asking? What will you need to have to your pharmacoeconomic justification makes sense? What is the role of clinical utility? In one information-packed hour, we will cover the essentials for successful laboratory capitalization.


Presenters include:

Rina Wolf, VP of Strategic Commercialization, Consulting and Industry Affairs at XIFIN, Inc.
Rina is a nationally recognized expert in the field of laboratory commercialization and reimbursement, with over 20 years of experience in the diagnostic laboratory industry, specializing in Molecular Diagnostic Laboratories.

Lew Shuster, CEO at Shuster Capital, a strategic and operating advisor to life science company executives and investors with a focus on contract services, lab reagents and instruments, clinical diagnostics, and selected medical devices. Lew has more than 25 years of experience in the industry with executive roles at Kemia, Life Technologies (previously Invitrogen), Pharmacopeia and Human Genome Sciences and sits on the board of many organizations including Response Biomedical, ADVENTRX and Complete Genomics.

  •